Enveric Biosciences (FRA:SLZ0) Cyclically Adjusted Book per Share: €126,523.17 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:SLZ0 Enveric Biosciences Inc FRA:SLZ0
30 GF Score
Price €56.07
! 1 Warning Sign
View Full Analysis

What is Enveric Biosciences Cyclically Adjusted Book per Share?

Enveric Biosciences FRA:SLZ0 30 Cyclically Adjusted Book per Share is €126,523.17 as of Jun. 2026. GuruFocus rates FRA:SLZ0 with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Enveric Biosciences's adjusted book value per share for the three months ended in Jun. 2026 was €1.783. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €126,523.17 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Enveric Biosciences's average Cyclically Adjusted Book Growth Rate was -14.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -21.50% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -8.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Enveric Biosciences was 14.10% per year. The lowest was -25.20% per year. And the median was -21.50% per year.

As of today (2026-08-26), Enveric Biosciences's current stock price is €56.07. Enveric Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €126,523.17. Enveric Biosciences's Cyclically Adjusted PB Ratio of today is 0.00.


Enveric Biosciences  (FRA:SLZ0) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Enveric Biosciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=56.07/126523.17
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Enveric Biosciences Cyclically Adjusted Book per Share Related Terms


Enveric Biosciences Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Enveric Biosciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enveric Biosciences Cyclically Adjusted Book per Share Chart

Enveric Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,599.84 5,073.86 4,448.05 3,580.54 51,115.76

Enveric Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14,056.89 25,449.05 51,115.76 93,035.74 126,523.17

FRA:SLZ0 vs ALZN, SILO, BGMS: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Enveric Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enveric Biosciences Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enveric Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Enveric Biosciences's Cyclically Adjusted PB Ratio falls into.


FRA:SLZ0
30GF Score
Enveric Biosciences Inc FRA:SLZ0
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enveric Biosciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Enveric Biosciences's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.783/333.9520*333.9520
=1.783

Current CPI (Jun. 2026) = 333.9520.

Enveric Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 0.000 246.819 0.000
201712 0.000 246.524 0.000
201803 0.000 249.554 0.000
201806 0.000 251.989 0.000
201809 0.000 252.439 0.000
201812 0.000 251.233 0.000
201903 0.000 254.202 0.000
201906 0.000 256.143 0.000
201909 0.000 256.759 0.000
201912 0.000 256.974 0.000
202003 0.000 258.115 0.000
202006 0.000 257.797 0.000
202009 0.000 260.280 0.000
202012 2,781.000 260.474 3,565.502
202103 7,976.500 264.877 10,056.623
202106 7,810.000 271.696 9,599.571
202109 15,687.333 274.310 19,098.160
202112 4,935.250 278.802 5,911.495
202203 3,698.833 287.504 4,296.402
202206 3,463.167 296.311 3,903.100
202209 1,922.333 296.808 2,162.903
202212 1,154.167 296.797 1,298.653
202303 809.917 301.836 896.094
202306 375.000 305.109 410.450
202309 190.250 307.789 206.422
202312 119.600 306.746 130.208
202403 145.439 312.332 155.506
202406 114.136 314.175 121.321
202409 71.200 315.301 75.412
202412 26.684 315.605 28.235
202503 17.592 319.799 18.371
202506 7.516 322.561 7.781
202509 5.685 324.800 5.845
202512 3.360 324.054 3.463
202603 2.319 330.213 2.345
202606 1.783 333.952 1.783

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €126,523.17 mean?
Enveric Biosciences (FRA:SLZ0) has a Cyclically Adjusted Book per Share of €126,523.17 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Enveric Biosciences and its competitors.
Is Enveric Biosciences' Cyclically Adjusted Book per Share too high?
Enveric Biosciences' current Cyclically Adjusted Book per Share is €126,523.17. Overall, Enveric Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Enveric Biosciences' Cyclically Adjusted Book per Share compare to ALZN and SILO?
Enveric Biosciences' Cyclically Adjusted Book per Share of €126,523.17 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Enveric Biosciences and its competitors. Enveric Biosciences's current Cyclically Adjusted Book per Share is €126,523.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enveric Biosciences stock overvalued right now?
Enveric Biosciences (FRA:SLZ0) has a current Cyclically Adjusted Book per Share of €126,523.17. The current Cyclically Adjusted Book per Share is €126,523.17. Enveric Biosciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Enveric Biosciences (FRA:SLZ0), the current Cyclically Adjusted Book per Share is €126,523.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enveric Biosciences Business Description

Other Exchanges ENVB:USA
Address 245 First Street, 18th Floor, Riverview II, Cambridge, MA, USA, 02142
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
30GF Score

Get the complete analysis for FRA:SLZ0

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€56.07
Price